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Bleeding complications and subsequent transfusion of allogeneic blood products constitute important clinical problems in cardiac surgery associated with 
increased morbidity and mortality.1–3 The etiology of bleed-
ing after cardiac surgery performed with cardiopulmonary 
bypass (CPB) is complex and involves activation of coagu-
lation and fibrinolysis, generation of nonhemostatic throm-
bin, and initiation of a systemic inflammatory response.4 
In addition, procedural factors such as hemodilution and 
hypothermia as well as perioperative use of platelet inhibi-
tors cause imbalance to the hemostatic equilibrium. Clinical 
studies have shown that thrombin generation during car-
diac surgery, especially at the initiation of CPB and dur-
ing myocardial reperfusion, may contribute to myocardial 
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BACKGROUND: Antifibrinolytics have been used for 2 decades to reduce bleeding in cardiac 
surgery. MDCO-2010 is a novel, synthetic, serine protease inhibitor. We describe the first experi-
ence with this drug in patients.
METHODS: In this phase II, double-blind, placebo-controlled study, 32 patients undergoing 
isolated primary coronary artery bypass grafting with cardiopulmonary bypass were randomly 
assigned to 1 of 5 increasing dosage groups of MDCO-2010. The primary aim was to evaluate 
pharmacokinetics (PK) with assessment of plasmatic concentrations of the drug, short-term 
safety, and tolerance of MDCO-2010. Secondary end points were influence on coagulation, 
chest tube drainage, and transfusion requirements.
RESULTS: PK analysis showed linear dosage-proportional correlation between MDCO-2010 infu-
sion rate and PK parameters. Blood loss was significantly reduced in the 3 highest dosage 
groups compared with control (P = 0.002, 0.004 and 0.011, respectively). The incidence of 
allogeneic blood product transfusions was lower with MDCO-2010 4/24 (17%) vs 4/8 (50%) 
in the control group. MDCO-2010 exhibited dosage-dependent antifibrinolytic effects through 
suppression of D-dimer generation and inhibition of tissue plasminogen activator-induced lysis 
in ROTEM analysis as well as anticoagulant effects demonstrated by prolongation of activated 
clotting time and activated partial thromboplastin time. No systematic differences in markers of 
end organ function were observed among treatment groups. Three patients in the MDCO-2010 
groups experienced serious adverse events. One patient experienced intraoperative thrombosis 
of venous grafts considered possibly related to the study drug. No reexploration for mediastinal 
bleeding was required, and there were no deaths.
CONCLUSIONS: This first-in-patient study demonstrated dosage-proportional PK for MDCO-2010 
and reduction of chest tube drainage and transfusions in patients undergoing primary coronary 
artery bypass grafting. Antifibrinolytic and anticoagulant effects were demonstrated using vari-
ous markers of coagulation. MDCO-2010 was well tolerated and showed an acceptable initial 
safety profile. Larger multi-institutional studies are warranted to further investigate the safety 
and efficacy of this compound.  (Anesth Analg 2014;119:16–25)
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damage and impaired hemostasis.5 Therefore, inhibition 
of thrombin generation might provide additional benefits 
besides reducing transfusion requirements.
Effective and safe pharmacological interventions to 
reduce bleeding complications are limited. Aprotinin, a 
nonspecific serine protease inhibitor, was widely used for 
2 decades to reduce bleeding and allogeneic transfusions 
in cardiac surgery but was withdrawn from the market 
in 2007 because of suspected increased mortality in 1 par-
ticular study.6 The only currently available antifibrinolytic 
drugs are the lysine analogues (epsilon-aminocaproic acid 
and tranexamic acid), which have also been questioned 
with respect to their safety profile.7–9 The nonspecific 
protease inhibitor aprotinin inhibits all serine proteases 
 dosage-dependently; in contrast, the lysine analogues are 
specific inhibitors of plasminogen/plasmin without any 
other direct inhibitory properties. Recently, efforts have 
been made to develop new compounds with strong antifi-
brinolytic efficacy, as well as additional favorable properties 
with respect to coagulation and inflammation, that may not 
compromise patient safety.
MDCO-2010 is a synthetic small molecule, acting as an 
active site inhibitor of plasmin and plasma kallikrein, both 
of which are considered to be pivotal in mediating impaired 
hemostasis during and after CPB.10 In addition, MDCO-2010 
is an inhibitor of coagulation factors Xa, Xia, and activated 
Protein C.11,12 It has the potential to mitigate both exces-
sive fibrinolysis and thrombin generation during cardiac 
surgery. MDCO-2010 competitively inhibits the amidolytic 
activity of human serine proteases with the strongest affin-
ity for plasma kallikrein and plasmin. Compared with apro-
tinin, the compound is substantially more potent against 
plasma kallikrein and factors Xa and XIa, but both inhibitors 
are much less effective against thrombin.12 Although apro-
tinin has demonstrated superior efficacy in comparison to 
lysine analogues,13 it is of biologic origin and has antigenic 
properties.14 MDCO-2010 is a serine protease inhibitor with 
comparable mode of action as aprotinin, but as a synthetic 
small molecule, it is unlikely to result in allergic reactions.
The aim of this phase II, double-blind,  placebo-controlled 
study was to evaluate pharmacokinetics (PK) with assess-
ment of plasmatic concentrations, initial safety, and tol-
erance of increasing dosages of MDCO-2010 in cardiac 
surgical patients. Secondary end points included influence 
of MDCO-2010 on coagulation, chest tube drainage, and 
transfusion requirements.
METHODS
After receiving approval from the Swiss regulatory author-
ity (SwissMedic, No. 2010DR2212) and the regional ethics 
committee (Kantonale Ethikkommission Bern, No. 111/10), 
written informed consent was obtained from all participat-
ing patients before study enrollment. The trial was registered 
at ClinicalTrials.gov NCT01535222. Between November 2010 
and May 2011, 34 patients scheduled for isolated primary 
coronary artery bypass grafting (CABG) surgery at a single 
center (University Hospital Berne, Switzerland) were asked to 
participate in the study, and all but one agreed. After induction 
of anesthesia, 1 patient was found to have clinically relevant 
ischemic mitral regurgitation requiring mitral annuloplasty. 
This patient was withdrawn from the study before dosing and 
not included in any of the safety or efficacy analyses.
Men or postmenopausal women were enrolled if the 
scheduled operation was elective and performed with CPB. 
Exclusion criteria were previous cardiac surgery, body 
weight <55 kg or >110 kg, major surgical procedures within 
30 days of entry, placement of a drug-eluting stent within 
12 months or of a bare-metal stent within 6 weeks, left ven-
tricular ejection fraction <35%, preoperative coagulation 
abnormalities (platelet count <100,000/mm3 or interna-
tional normalised ratio >1.5 or activated partial thrombo-
plastin time (aPTT) >1.5 × upper limit of normal), refusal 
of allogeneic blood transfusion, preoperative hemoglobin 
<11 g/dL for men patients or <10 g/dL for women patients, 
administration of thienopyridines within 5 days of sur-
gery, creatinine clearance <60 mL/min, history of stroke 
or transient ischemic attack within 3 months of surgery, 
known  heparin-induced thrombocytopenia, known his-
tory of thrombophilia (e.g., deep vein thrombosis or pul-
monary embolism), allergic condition, active liver disease, 
and any condition requiring chronic immunosuppressive 
medication.
Patient Management
Patients were treated in 5 sequential cohorts randomized 
by a computer-generated list to blocks of 4 patients for 
cohort 1 and 2 and 8 patients for cohorts 3 to 5, receiving 
either MDCO-2010 or placebo (normal saline) in a ratio of 
3:1 within each cohort. The starting dosage of MDCO-2010 
in this study was based on dosages considered safe in a 
randomized, placebo-controlled, phase I study in healthy 
volunteers (unpublished data), and the highest dosage was 
expected to result in plasma concentrations approximately 
900 nmol/L.11 Blinded study medication was prepared by 
the local pharmacy. After completion of each cohort, a Safety 
Surveillance Team composed of clinical experts reviewed 
blinded safety and PK data and determined whether it was 
safe to escalate to the next dosage level. The randomization 
algorithm resulted in 6 treatment groups: 5 groups with 
escalating dosages of MDCO-2010 (MDCO-2010 group 1–5) 
and 1 control group (saline placebo). A doubling of dosages 
was planned per each new escalating dosage cohort; how-
ever, dosage adjustment was permitted as part of the pro-
tocol. The Safety Surveillance Team decided to reduce the 
dosage escalation to cohort 4 and 5, respectively, based on 
higher than expected plasma concentrations of MDCO-2010 
in the first 3 study groups.
Study drug was administered via a central venous cath-
eter with an initial loading dosage followed by a continuous 
infusion until sternal closure. As a measure of safety, drug 
infusion was started only, but immediately, after heparin-
ization; since in this first-in-patient study, a possible proco-
agulant effect could not be excluded. Patients randomized 
to MDCO-2010 received initial loading dosages of 0.005, 
0.011, 0.027, 0.047, or 0.094 mg/kg, followed by continuous 
infusion of 0.0125, 0.025, 0.0625, 0.109, or 0.219 mg/kg/h, 
respectively. In addition, 0.02, 0.04, 0.09, 0.15, and 0.31 mg 
MDCO-2010, respectively, were added to the pump prime 
fluid. Patients in the control group received equal volumes 
of saline in a blinded fashion.
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All procedures were performed according to a stan-
dardised surgical protocol using a minimised extracor-
poreal circulation system (MECC, Jostra AG, Hirrlingen, 
Germany) with a priming volume of 600 mL(Ringer’s lac-
tate solution, Sintetica-Bioren SA, Couvet, Switzerland) in 
which 1 g calcium was added (Calcium-Sandoz, Sandoz, 
Cham, Switzerland). Surgery was performed under mild 
hypothermia of 32°C to 34°C, via midline sternotomy, 
and the left internal mammary artery was used as bypass 
conduit in all study patients. Antegrade cardioplegia was 
given via the aortic root (100 mL Cardioplexol®, Bichsel 
Laboratory, Interlaken, Switzerland). Cardiotomy suction 
(SmartSuction, Cardiosmart AG, Muri, Switzerland) was 
applied during CPB. Remaining blood from the operating 
field and the extracorporeal circuit was washed using a 
cell saver device (Autolog, Medtronic, Minneapolis, MN) 
and retransfused to the patient throughout the duration 
of the operation. All patients received a standardised 
anesthesia regimen using sufentanil, midazolam, and 
isoflurane.
For CPB, unfractionated porcine mucosa heparin 
(Liquemin®; Roche, Basel, Switzerland) was administered IV 
at a dosage of 400 units/kg, with 10,000 units added to the 
priming of the CPB circuit to achieve a target activated clotting 
time (ACT) of >480 seconds. Heparinization was controlled 
by the kaolin ACT every 20 minutes with the Medtronic ACT 
Plus® System (Medtronic, Minneapolis, MN). An additional 
bolus of 125 U/kg of heparin was applied if the kaolin ACT 
was <400 seconds during CPB. At the end of CPB, heparin 
reversal was accomplished with protamine chloride (1:1 ratio 
of the total heparin dosage). Sufficient reversal of heparin 
by protamine was controlled using the Hepcon® HMS Plus 
(Medtronic, Minneapolis, MN).
Intraoperative administration of tranexamic acid or 
ε-aminocaproic acid was prohibited by the protocol, but 
it was not excluded during the postoperative period. 
Colloids and crystalloids were administered at the discre-
tion of the attending anesthesiologist. Packed red blood 
cells were transfused if the hemoglobin was <7 g/dL 
during CPB. If after CPB hemoglobin concentration was 
between 7 and 10 g/dL, the decision to transfuse allogenic 
red blood cells was based on clinical signs of anemia. Fresh 
frozen plasma was given if the prothrombin time was >1.5 
× upper limit of normal, and signs of increased bleeding 
were evident; the criteria for transfusion of platelets was a 
platelet count <100,000 mm3 and suspected loss of platelet 
function. Both fresh frozen plasma and platelets were only 
administered if excessive chest tube drainage (>200 mL/h) 
was recorded.
Postoperatively, a standardised treatment protocol was 
applied. The patients’ lungs were ventilated in the intensive 
unit until the patients were normothermic and hemody-
namically stable. Blood loss via chest tubes was determined 
at 6, 12, and 24 hours postoperatively. Indication for surgi-
cal reexploration was driven by clinical judgment and blood 
loss >200 mL/h for 2 consecutive hours. Massive transfu-
sion was defined as transfusion of ≥10 units of red blood 
cells within 24 hours postoperatively or the need for surgi-
cal reexploration because of hemorrhage.
Blood Sampling
Blood samples were drawn from the arterial or central 
venous line at 13 time points: before heparin administra-
tion (T1), before CPB initiation (T2), 15, 30, and 60 minutes 
after CPB start (T3, T4, and T5), 10 minutes after protamine 
administration (T6), at sternal closure (T7), 15 and 30 min-
utes, and 4 hours after sternal closure (T8, T9, and T10), and 
on days 1, 2, and 4 after surgery.
Citrated blood was drawn and directly centrifuged 
(3000g, 10 minutes). The plasma was frozen immediately 
in multiple aliquots and stored at −80°C until assayed. 
D-Dimer levels were assessed using the D-Dimer PLUS 
immunoturbidometric assay (Dade Behring, Marburg, 
Germany; reference range: 0.06–0.25 mg/L). Thrombin 
activation, determined by the formation of prothrombin 
fragment 1+2 (F1+2), was measured using a microtiter 
plate-based sandwich immunoassay (Enzygnost F1+2, 
monoclonal, Dade Behring, Germany; reference range 69–
229 pmol/L). The aPTT was determined with a Pathromtin 
SL reagent (Dade Behring, Marburg, Germany; reference 
range: 25–37 seconds). Cardiac troponin T was measured 
on Elecsys 2010 analyzer with an enzyme immunoassay 
based on electrochemiluminescence (Roche Diagnostics, 
Rotkreuz, Switzerland; lower detection limit 0.01 ng/mL). 
MDCO-2010 plasma concentrations were determined using 
a validated method with liquid chromatography-tandem 
mass spectrometry detection.12 All measurements were per-
formed immediately after thawing the plasma.
Influence on whole blood clotting was assayed with a 
multichannel ROTEM® analyzer (Tem Innovations GmbH, 
Munich, Germany) using EXTEM and INTEM reagent to 
activate coagulation. Fibrinolysis in whole blood was stud-
ied using a modified ROTEM analysis using EXTEM reagent 
with added recombinant tissue plasminogen activator 
(Actilyse®, Boehringer Ingelheim, Germany; final concen-
tration of 100 U/mL in the test tube), allowing measure-
ment of lysis onset time, defined as the time needed for clot 
firmness to decrease by 15% of maximum clot firmness.12 A 
total of 140 mL blood was drawn for study purposes.
Safety Evaluation
Patients were carefully monitored for adverse events (AE) 
and serious adverse events (SAE). The study included 
evaluations of safety, thrombotic, PK, and pharmacody-
namic end points. Safety end points included a summary 
of all AEs and SAEs, as well as vital signs (arterial blood 
pressure, heart rate, and body temperature), and clinically 
significant changes in laboratory markers of hematology, 
chemistry, and coagulation. In addition to routine variables, 
clinical laboratory assessment included markers of hista-
mine release and complement activation, as well as inter-
leukin (IL)-6 and IL-10. For all AEs and SAEs, the causal 
relationship to study medication was assessed by the inves-
tigators. Thrombotic end points were defined as thrombotic 
or embolic events or laboratory signs of hypercoagulability. 
Early graft patency was examined intraoperatively before 
pericardial closure using transit time flow measurement 
(CardioMed, Medi.Stim, Norway). Periprocedural myo-
cardial infarction (MI) was defined as creatine kinase MB 
(CK-MB) ≥5 times local laboratory upper limit of normal 
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and new pathological Q waves or new left bundle branch 
block, or imaging evidence of new loss of viable myocar-
dium.15 Acute kidney injury was defined according to the 
RIFLE criteria.16
Statistical Analysis
Statistical analysis was performed using the SAS/STAT® 
software (SAS Institute Inc., Cary, NC). If not otherwise 
stated, distributions of quantitative data were described 
by reporting the median with 25th to 75th percentiles. 
Categorical variables were reported as absolute num-
bers and percentages. The Fisher exact test was used to 
investigate differences in the frequency distribution of 
critical events among the dosing groups. To assess inter-
group differences at single predetermined time points, the 
Wilcoxon rank-sum test was used. PK analysis of plasma 
concentration versus time and the relationship between 
maximum plasma concentration and area under plasma 
 concentration-time curve (AUC) as well as pharmacody-
namic markers were evaluated using Phoenix WinNonlin 
Version 6.2 (Pharsight, Mountain View, CA). Linear (con-
stant or linear) Imax, inhibitory Imax, and sigmoid inhibi-
tory Imax models were applied to the data. All statistical 
tests were performed 2-sided, and the level of statistical 
significance was set to P < 0.05. Because this was a phase 
2 study with the primary aim of evaluating PK, short-term 
safety, and tolerance of MDCO-2010, no P value adjustment 
was applied for multiple comparisons.
RESULTS
Twenty-four patients received MDCO-2010, and 8 patients 
received placebo. Demographics and procedural variables 
are summarised in Table 1. No clinically significant differ-
ences among the 6 study groups were observed with respect 
to patient demographics, clinical characteristics at baseline, 
and operative variables. The total heparin dosage adminis-
tered during surgery did not differ significantly among the 
study groups (Table 1).
Pharmacokinetic Results
All 24 subjects in the MDCO-2010 treatment groups were 
included in the PK analysis. MDCO-2010 plasma levels 
increased rapidly with the start of bolus infusion and 
remained stable during the infusion (Fig.  1A). Mean (± 
standard derivation [SD]) steady-state plasma concen-
trations (Css) in the escalating dosing groups were 50 ± 
4, 96 ± 20, 268 ± 40, 479 ± 102, and 1009 ± 204 ng/mL, 
respectively. After the end of the infusion, MDCO-2010 
plasma levels decreased approximately 40% in the first 
30 minutes and had a mean (± standard error [SE]) ter-
minal half-life of 81 (±7) minutes. Total body clearance 
decreased across the 5 dosage groups from 220 ± 78 to 153 
± 19 mL/min. The steady-state volume of distribution 
was larger than central blood volume. Systemic exposure 
parameters Css and AUCinf increased dosage proportion-
ally. There was a significant linear correlation between 
Css and infusion rate of MDCO-2010 with a Pearson r 
of 0.98 [95% CI, 0.95–0.99] (Fig. 1B). AUCinf values were 
Table 1.  Patient Characteristics and Operative Variables
Control group 
(n = 8)
MDCO-2010 groups All patients
1 (n = 3) 2 (n = 3) 3 (n = 6) 4 (n = 6) 5 (n = 6)  (n = 32)
Age, y 68.5  
(60; 70)
62.0  
(52; 76)
65.0  
(50;71)
62.0  
(55; 65)
69.0  
(63; 77)
65.0  
(52; 73)
64.5  
(59; 71)
Female sex, n (%) 0 0 0 0 2  
(33)
3  
(50)
5  
(15.6)
Body mass index, kg/m2 23.7  
(22;27)
26.8  
(21; 27)
27.9  
(25; 29)
26.7  
(25; 28)
27.2  
(26; 29)
26.7  
(25; 29)
26.6  
(24; 28)
Diabetes, n (%) 0 0 0 1(17) 2  
(33)
2  
(33)
5  
(16)
Hypertension, n (%) 6  
(75)
3  
(100)
2  
(67)
5  
(83)
5  
(83)
6  
(100)
27  
(84.4)
Prior MI, n (%) 2  
(25)
0 2  
(67)
3  
(50)
3  
(50)
0 10  
(31)
LVEF (%) 60  
(60; 65)
60  
(55; 74)
63  
(60; 64)
64  
(60; 72)
65  
(60; 70)
65  
(60; 65)
64  
(60; 65)
CPB duration, min 67  
(59; 77)
45  
(44; 68)
77  
(38; 79)
79  
(71; 82)
56  
(45; 81)
57  
(38; 63)
65  
(50; 79)
Cross-clamp time, min 43  
(37; 56)
30  
(28; 39)
53  
(30; 54)
47  
(43; 60)
34  
(31; 43)
34  
(26; 38)
39  
(31; 47)
No. grafts, n 3.5  
(3; 4)
3  
(2; 4)
4  
(2; 5)
3  
(3; 4)
3  
(3; 4)
3  
(2; 4)
 3  
(3; 4)
Total heparin dosage during 
surgery, units
38,250  
(35,750;  
39,625)
35,000  
(32,500; 
42500)
40,000  
(37,500; 
47,500)
36000  
(33250;  
38000)
40,000  
(37,500;  
41,750)
32,900  
(31,250; 
34,700)
36,000  
(32,875;  
40,000)
ICU stay, h 20  
(20; 22)
20  
(17; 20)
21  
(18; 21)
20  
(18; 22)
18.5  
(17; 21)
21  
(20; 22)
20  
(18; 21)
Hospital stay, d 7.9  
(6.5; 8.0)
7.9  
(5.8; 9.0)
6.1  
(5.0; 6.8)
6.9  
(6.0; 7.8)
7.5  
(7.0; 10.9)
7.9  
(6.5; 8.0)
7.4  
(6.2; 8.0)
30-d mortality, n 0 0 0 0 0 0 0
Data are median (25th; 75th percentiles) unless otherwise specified.
LVEF = left ventricular ejection fraction; CPB = cardiopulmonary bypass; ICU = intensive care unit.
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linearly correlated with total dosage of  MDCO-2010 with 
a Pearson r of 0.97 [CI, 0.93–0.99].
Coagulation and Fibrinolysis
ACT values were prolonged in MDCO-2010 groups 3 
through 5 compared with placebo (Table  2). Significantly 
prolonged ACT values were evident in groups 4 and 5 after 
full reversal of heparin with protamine (124 [113; 142] in 
control, 166 [149; 171] in group 4, and 181 [170; 187] sec-
onds in group 5, respectively; both P < 0.05), and up to 30 
minutes after sternal closure (Table 2). Dosage-related pro-
longation of aPTT was present at sternal closure in groups 
2 through 5 (control 43 [39; 47] vs 97 [94; 109] seconds in 
group 5; P < 0.05, Table 2), but no positive association was 
found between prolonged aPTT and blood loss. The aPTT 
values returned to normal 4 hours after sternal closure. A 
 dosage-dependent increase of EXTEM and INTEM clotting 
times was found at sternal closure and 15 minutes thereaf-
ter (Table 2). Clot firmness in ROTEM analyses at 10 and 
30 minutes were not relevantly influenced by MDCO-2010 
(data not shown). Significant suppression of D-dimer gen-
eration was observed at sternal closure in dosage groups 
4 and 5. In addition, significant dosage-dependent lysis 
onset time prolongation was observed in dosage groups 3 
through 5 (Table 2). The course of F1,2 did not demonstrate 
any significant difference over time among the groups (data 
not shown). Anticoagulant effects of MDCO-2010 on ACT, 
aPTT, and EXTEM clotting times demonstrated as absolute 
changes between baseline measurements and correspond-
ing values at sternal closure are summarised in Figure 2.
Blood Loss and Transfusions
Twelve-hour postoperative chest tube drainage was signifi-
cantly reduced at higher MDCO-2010 dosages: 900 (815; 950) 
in the control group vs 350 (300; 370) in group 3, 350 (300; 
450) in group 4, and 360 (350; 400) mL in group 5; P = 0.002, 
0.004, and 0.011, respectively (Table 3). In the control group 
4/8 (50%), patients received transfusion of allogeneic blood 
Figure 1. Pharmacokinetic data in 
 MDCO-2010 treatment groups. A, Mean 
plasma concentrations. B, Steady-state 
concentrations (Css) defined as mean of 
plasma concentrations at sampling points 
T4 to T7. T1 = before heparin; T2 = before 
cardiopulmonary bypass (CPB); T3 = 15 
minutes on CPB; T4 = 30 minutes on CPB; 
T5 = 60 minutes on CPB; T6 = after prot-
amine; T7 = sternal closure; T8 = 15 min-
utes after sterna closure; T9 = 30 minutes 
after sterna closure.
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products during the hospital stay compared with 4/24 
(17%) in the MDCO-2010 groups. MDCO-2010 patients who 
received transfusions required also less volume of blood 
products than control patients. Hemoglobin concentra-
tions were not different among the treatment groups during 
the study period. Two patients in the placebo group were 
treated with tranexamic acid postoperatively because of 
excess bleeding, but none in MDCO-2010 groups. Although 
still in the intensive care unit, 1 patient in the placebo group 
underwent local surgical revision of the saphenous vein 
harvest site because of diffuse bleeding. No patient in the 
study underwent reoperation for any other causes. No mas-
sive transfusions occurred.
Adverse Events and Drug Tolerance
A total of 21/24 (87.5%) patients in the MDCO-2010 groups 
experienced an AE, compared with 7/8 (87.5%) patients 
in the placebo group. In MDCO-2010 groups, 2/24 (8.3%) 
patients experienced an AE that was considered possibly 
related to study drug, compared with 2/8 (25.0%) patients 
in the placebo group. There were no noteworthy differences 
in the overall frequency of AEs among treatment groups or 
Table 2.  Pharmacodynamic Effects on Markers of Coagulation and Fibrinolysis
Variable
Control group  
(n = 8)
MDCO-2010 groups
1 (n = 3) 2 (n = 3) 3 (n = 6) 4 (n = 6) 5 (n = 6)
ACT, s
  Baseline 127 (112; 142) 111 (110; 131) 128 (109; 129) 117 (110; 123) 124 (116; 145) 108 (106; 120)
  Pre-CPB 638 (570; 779) 907 (593; 999) 604 (570; 734) 760 (599; 809) 767 (719; 841) 879 (742; 999)
  15 min on CPB 618 (536; 849) 745 (688; 801) 628 (570; 778) 750 (653; 999) 789 (734; 916) 958 (832; 999)
  30 min on CPB 693 (566; 949) 745 (719; 771) 733 (593; 999) 999 (699; 999) 940 665; 999) 999 (848; 999)
  After protamine 124 (113; 142) NR 118 (112; 123) 133 (119; 137) 166 (149; 171) 181 (170; 187)
  Sternal closure 151 (123; 156) 132 (128; 147) 148 (130; 307) 122 (111; 130) 147 (145; 159) 187 (178; 194)
  15 min after  
 sternal  
 closure
148 (118; 155) 130 (118; 145) 138 (97; 141) 118 (113; 132) 169 (165; 178) 167 (165; 170)
  30 min after  
 sternal  
 closure
133 (126; 141) 130 (124; 150) 120 (118; 168) 123 (121;126) 156 (147; 165) 159 (149; 173)
aPTT, seconds
  Baseline 35 (33; 38) 31 (28; 32) 35 (29; 38) 34 (32; 34) 33 (31; 42) 31 (30; 33)
  Sternal closure 43 (39; 47) 42 (41; 43) 52 (45; 250) 61 (57; 71) 82 (75; 96) 97 (94; 109)
  15 min after  
 sternal  
 closure
43 (40; 49) 41 (39; 42) 53 (50; 55) 52 (47; 58) 73 (66; 88) 85 (85; 99)
  30 min after  
 sternal  
 closure
43 (40; 52) 43 (42; 44) 48 (42; 56) 47 (40; 59) 68 (60; 81) 78 (76; 90)
  4 h after sternal 
 closure
38 (36; 47) 39 (39; 39) 38 (37; 40) 49 (35; 49) 44 (40; 52) 41 (39; 51)
INTEM CT, s
  Baseline 178 (172; 188) 177 (153; 186) 161 (159; 260) 170 (159; 173) 166 (154; 186) 173 (158; 180)
  After protamine 212 (182; 230) 307 (186; 402) 244 (220; 569) 263 (228; 311) 302 (297; 332) 391 (360; 432)
  15 min after  
 sternal  
 closure
200 (192; 226) 204 (161; 250) 190 (175; 330) 228 (196; 282) 266 (247; 269) 325 (263; 369)
EXTEM CT, s
  Baseline 57 (55; 61) 62 (62; 112) 64 (55; 74) 66 (64; 70) 58 (54; 66) 51 (48; 55)
  Sternal closure 71 (68; 84) 81 (68; 119) 83 (81; 90) 94 (88; 110) 126 (97; 131) 120 (110; 147)
tPA-EXTEM LOT, s
  Baseline 747 (706; 945) 713 (545; 1232) 779 (747; 854) 810 (562; 895) 937 (782; 1390) 988 (879; 1125)
  Sternal closure 2470 (1943; 2707) 2925 (2607; 3243) 2480 (2348; 2611) 3271 (2772; 3490) 3515 (1949; 3600) 3600 (2532; 3600)
  15 min after  
 sternal  
 closure
2559 (1857; 2771) 2868 (1448; 3175) 2472 (835; 3324) 3202 (2945; 3441) 3298 (2005; 3600) 3466 (2292; 3600)
tPA-EXTEM Lysis 
Index 30 min, %
  Baseline 0.5 (0.2;0.5) 0 (0;42) 3 (1;22) 3.5 (1;11) 5 (1;29) 2 (1;3)
  Sternal closure 97 (81;99) 99.5 (99;100) 100 (92;100) 99.5 (99;100) 100 (91;100) 99.5 (98;100)
  15 min after  
 sternal  
 closure
97.5 (77;99) 98 (36;100) 97 (0;98) 100 (100;100) 99.5 (91;100) 99.5 (96;100)
D-Dimer, mg/L
  Baseline 0.3 (0.3; 0.3) 0.4 (0.2; 0.4) 0.9 (0.5; 1.2) 0.5 (0.3; 0.6) 0.5 (0.4; 0.7) 0.3 (0.3; 0.3)
  Sternal closure 2.4 (1.7; 3.9) 3.4 (2.2; 3.7) 3.9 (1.4; 5.2) 2.4 (0.9; 4.0) 2.0 (1.8; 2.1) 0.9 (0.6; 1.6)
Data are median (25th; 75th percentiles).
ACT = activated clotting time; aPTT = activated partial thromboplastin time, CT = clotting time; LOT = lysis onset time; NR = not recorded; CPB = cardiopulmonary 
bypass; tPA = tissue plasminogen activator.
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between the MDCO-2010 treatment groups and the placebo 
group (Table  4). Increases in alanine aminotransferase, bili-
rubin, and blood CK-MB were evenly distributed between 
treatment cohorts and placebo with no apparent dosage cor-
relation associated with study drug that was consistent with 
other measured variables (histamine release, complement 
activation, IL-6, and IL-10; data not shown). None of the study 
patients experienced postoperative acute kidney injury.
Three patients in the MDCO-2010 treatment groups 
experienced 5 SAEs. One patient (MDCO-2010 dosage 
group 3) experienced a stroke and acute MI 7 days after 
the procedure and after hospital discharge. Diagnosis of 
heparin-induced thrombocytemia was confirmed, and the 
event was classified by the investigator as unlikely related 
to the study drug. Another patient (MDCO-2010 dosage 
group 5) had an air leakage through one of the thoracic 
drainages that caused prolonged hospitalization. A third 
patient (MDCO-2010 dosage group 5) experienced vascu-
lar graft thrombosis. At the end of surgery, graft thrombosis 
occurred in 2 saphenous vein grafts, which showed limited 
flow after heparin reversal. This graft occlusion was consid-
ered possibly related to study drug. There were no deaths or 
withdrawals because of AEs in this study.
DISCUSSION
Antifibrinolytic drugs have become increasingly popular in 
major surgery to reduce bleeding tendency. Inhibition of the 
fibrinolytic pathway results in decreased bleeding and con-
secutive need for transfusion requirements. This has been 
proven for both synthetic lysine analogues and aprotinin.13,17 
Tranexamic acid as well as  epsilon-aminocaproic acid is 
the commonly used synthetic lysine analogues, which act 
by blockade of the lysine-binding sites of plasminogen, 
thus preventing conversion to plasmin and degradation of 
fibrinogen to fibrin. The nonspecific serine protease inhibi-
tor aprotinin dosage-dependently inhibits several serine 
proteases and also has, thus, in addition to its antifibrino-
lytic activity, anticoagulant, and anti-inflammatory prop-
erties.18,19 Aprotinin, widely used for >20 years in cardiac 
surgery, was withdrawn from the market in 2007 because 
of safety concerns.6 However, recent revision of aprotinin’s 
risk/benefit profile has led to its reapproval in Canada.20 
Because of persistent concerns about the safety of aprotinin 
and tranexamic acid,7,8,21 it is prudent to investigate alterna-
tives to the conventional antifibrinolytic drugs.
In this first-in-patient study, we tested the novel, syn-
thetic, serine protease inhibitor MDCO-2010 for initial 
Figure 2. Anticoagulant effects of 
 MDCO-2010. ACT = activated clotting time, 
aPTT = activated thromboplastin time, and 
CT = EXTEM clotting time at multichannel 
ROTEM analyzer.
Table 3. Blood Loss and Transfusions
Variables Control group (n = 8)
MDCO-2010 groups
1 (n = 3) 2 (n = 3) 3 (n = 6) 4 (n = 6) 5 (n = 6)
Postoperative chest 
tube drainage, mL
  0 to 6 h 550 (350–800) 250 (200–450) 325 (220–400) 210 (175–230) 265 (200–350) 225 (200–250)
  0 to 12 h 900 (815–950) 450 (420–800) 595 (500–800) 350 (300–370)a 350 (300–450)a 360 (350–400)a
  0 to 24 h 1500 (1200–1750) 885 (550–1220) 1400 (1400–1400) 630 (500–900) 1000 (800–1200) 700 (550–950)
Patients receiving 
transfusions, n (%)
4 (50) 0 (0) 0 (0) 1 (17) 1 (17) 2 (33)
Average no. PRBC 
transfusions per 
patient, n
2.0 0 0 0.33 0.17 0.67
Total no. blood 
products, n
PRBC: 16 Platelets: 5 
FFP: 10
0 0 PRBC: 2 PRBC: 1 PRBC: 4
Data are median (25th–75th percentiles) unless otherwise specified.
FFP = fresh frozen plasma; PRBC = packed red blood cells.
aPost hoc analysis performed only at time point 12 hours postoperatively: P < 0.05 MDCO-2010 group versus control group
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safety and tolerance. We found predictable plasmatic con-
centrations and an acceptable initial safety profile of the 
drug. Increasing dosages of MDCO-2010 resulted in higher 
plasma concentrations. These correlations suggest linear 
PK for MDCO-2010 infusion during CABG surgery in the 
studied range of dosing. The highest dosage group was 
expected to have steady-state plasma levels of 900 nmol/L, 
as had been demonstrated in in vitro experiments.12 In a 
canine bypass model, IC50 for fibrinolysis inhibition as well 
as reduction of bleeding tendency was determined to be 600 
nmol/L.11 Plasma concentrations found in the current trial 
were slightly higher than expected from previous in vitro 
studies.12 We targeted plasma concentrations of 900 nmol/
mL but reached >1000 nmol/mL in patients in the highest 
dosing group. Of note, this study used a small CPB circuit 
with a priming volume of just 600 mL. Hemodilution by 
higher priming volumes may result in lower plasma con-
centrations of MDCO-2010, if the same dosages are applied. 
The relatively rapid decline of plasma concentrations after 
the end of the infusion predicts good control but necessi-
tates a continuous infusion of the drug.
Blood loss was significantly reduced compared with con-
trols in groups 3 to 5, with the 3 groups showing a similar 
level of reduction, suggesting a plateau effect. This may 
indicate that the infusion of 27 μg/kg followed by 62.5 
μg/kg/h combined with an additional bolus of 90 μg/
kg to the priming volume (dosage group 3) is sufficient to 
reduce bleeding. However, the present study only included 
patients with a low-risk profile of bleeding complications, 
in whom a more pronounced reduction of bleeding with 
higher dosages may not have been feasible. It is not yet 
known whether this may also be true for patients at higher 
risk for bleeding complications.
ACT is widely used to monitor anticoagulation during 
cardiac surgery. MDCO-2010 shows dosage-dependent 
inhibition of kallikrein and coagulation factors XIa and Xa;12 
therefore, a prolongation of ACT and aPTT values after 
MDCO-2010 exposure was expected. Previously, compara-
ble results have been demonstrated with the serine protease 
inhibitor aprotinin, and there has been a lengthy scientific 
discussion whether this prolongation is a real anticoagulant 
effect or reflects only an artificial in vitro effect.19,22,23 The 
current data demonstrate a median kaolin ACT at sternal 
closure of 187 (178; 194) seconds in the highest dosing group 
with a decline to 159 (149; 173) seconds 30 minutes there-
after. Concurrently, the aPTT values in the highest dosing 
group decreased from 97 (94; 109) to 78 (76; 90) seconds and 
were near the normal range 4 hours postoperatively: 41 (39; 
51) seconds. The ROTEM results run in parallel (Table 2). All 
these findings demonstrate that MDCO-2010 has a moderate 
and real anticoagulant effect in patients. It is interesting to 
note that there was no association between prolonged vari-
ables of intrinsic activation of coagulation and an increased 
amount of postoperative bleeding. This indicates that inhi-
bition of the intrinsic pathway did not provoke bleeding. Of 
note, with aprotinin, the aPTT was prolonged up to the first 
postoperative day compared with tranexamic acid.24
Recently, Kim et  al.25 investigated the in vitro effect of 
MDCO-2010 on ACT prolongation using different ACT 
systems and different activators: MDCO-2010 showed 
a concentration-dependent prolongation of ACT values 
regardless of the activators or the devices used for analysis. 
In addition, the kaolin ACT seemed to be less influenced 
by the drug than the celite-activated measurement. In our 
study, the kaolin ACT after heparin administration before 
CPB was 638 (570; 779) in the placebo group compared with 
879 (742; 999) seconds in the highest MDCO-2010 dosing 
group. This 27% increase in median values corresponds 
to the 15% to 35% increase found in the in vitro study of 
Kim et al.25 Further studies are needed to evaluate a reliable 
heparin management strategy and appropriate, clinically 
feasible monitoring when MDCO-2010 is used.
Graft patency is determined by various factors including 
the runoff at the distal coronary target vessel, the flow in 
the venous or arterial bypass graft, the quality of the surgi-
cal suture, and the balance of the coagulation/fibrinolytic 
state. Since the early days of antifibrinolytic therapy, there 
have been concerns regarding impaired graft patency.26,27 
Table 4.  Adverse Events
System organ class
Placebo group  
(n = 8) n (%)
MDCO-2010 groups All patients
1 (n = 3) n (%) 2 (n = 3) n (%) 3 (n = 6) n (%) 4 (n = 6) n (%) 5 (n = 6) n (%)  (N = 32) n (%)
Total overall 7 (87.5) 3 (100.0) 3 (100.0) 5 (83.3) 4 (66.7) 6 (100.0) 28 (87.5)
Blood and lymphatic 
system disorders
0 0 0 1 (16.7) 0 0 1 (3.1)
Cardiac disorders 1 (12.5) 0 0 1 (16.7) 2 (33.3) 2 (33.3) 6 (18.8)
General disorders 4 (50.0) 2 (66.7) 2 (66.7) 3 (50.0) 1 (16.7) 2 (33.3) 14 (43.8)
Injury, poisoning 
and procedural 
complications
3 (37.5) 0 0 2 (33.3) 0 1 (16.7) 6 (18.8)
Nervous system 
disorders
0 0 0 1 (16.7) 0 0 1 (3.1)
Psychiatric disorders 0 0 0 0 0 1 (16.7) 1 (3.1)
Renal and urinary 
disorders
0 0 0 0 1 (16.7) 0 1 (3.1)
Respiratory, thoracic, 
and mediastinal 
disorders
2 (25.0) 0 1 (33.3) 1 (16.7) 0 0 4 (12.5)
Skin and subcutaneous 
tissue disorders
0 0 0 0 1 (16.7) 0 1 (3.1)
Surgical procedures 1 (12.5) 0 0 0 0 0 1 (3.1)
Vascular disorders 2 (25.0) 0 0 1 (16.7) 0 0 3 (9.4)
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One patient in the highest dosing group experienced graft 
thrombosis of the venous bypass grafts after triple CABG 
that was classified by the investigator as possibly related 
to study drug. In this patient, the runoff to the right coro-
nary artery was limited by size and quality of the target 
vessel, and there was no flow in the graft before sternal 
closure. Reevaluation of the graft revealed thrombosis; 
however, even after revision, there was no flow on this 
graft. Postoperatively, the target vessel was treated by a 
percutaneous intervention but without success. The patient 
experienced a perioperative MI. All other types of AEs were 
similarly distributed among the study groups.
This study has some limitations. First, because it was an 
initial safety and dosage-finding study to determine PK, the 
number of patients was too small to substantiate a signifi-
cant influence on bleeding, transfusion, and AEs. However, 
the results demonstrated that MDCO-2010 seems to have 
the potential to reduce bleeding after cardiac surgery. 
Second, we included only low-risk patients in this study, 
which is likely not the population that will benefit most 
from intensified antifibrinolytic therapy.28 Our study popu-
lation was a very homogenous class of patients, in which 
assessment of the plasmatic concentration could be well 
performed although the design of the study did not allow 
a full PK evaluation. Third, we did not include a control 
group of patients treated with other antifibrinolytics (e.g., 
tranexamic acid); however, efficacy was not selected as the 
primary end point in this phase II study.
In summary, in patients undergoing CABG surgery with 
CPB, MDCO-2010 provided clinically significant antifibri-
nolytic properties combined with measurable anticoagula-
tory activity. Our preliminary data from this first-in-patient 
study of MDCO-2010 point to clinical hemostatic efficacy 
with an acceptable safety profile.
Subsequently to this phase II study, a larger multicenter 
study has already been initiated based on the results of 
this trial. This double-blind, randomized study aimed to 
compare MDCO-2010 with both placebo and tranexamic 
acid (ClinicalTrials.gov NCT01530399). However, this 
study was discontinued in response to unexpected patient 
safety issues encountered during the trial. The cause of the 
safety issues and any potential link to the study drug are 
still under investigation; full publication of the results is 
intended after final evaluation. The future of this and simi-
lar drugs is uncertain at this point. E
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